Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Findings from the MajesTEC-1 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced NSCLC
Findings from the KRYSTAL-1 study
FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination with Ipilimumab for First-Line Treatment of Oesophageal Squamous Cell Carcinoma
Efficacy was evaluated in the CHECKMATE-648 study
High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent PD1 Blockade
Findings from a prospective phase II study with dostarlimab
Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive Biomarker to Improve Patients’ Selection for Pembrolizumab
Findings from the PEMBROSARC study on presence of tertiary lymphoid structures in patients with advanced soft tissue sarcomas
Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes
Findings from a combining analysis of MDS patient samples with CRISPR-DiR technology
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia
Evidence for efficacy is based on the results from the AZA-JMML-001 study
Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC
Findings from the largest circulating tumour cells study in patients with metastatic renal cell carcinoma
R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification of Patients with Intermediate-Risk Newly Diagnosed Multiple Myeloma
Second revision stems on the work of the European Myeloma Network within the European Union–funded HARMONY project
EMA Recommends Extension of Therapeutic Indications for Pembrolizumab
Extended indications concern the treatment of melanoma in adolescents aged 12 years and older and in adjuvant setting extend to Stage IIB and IIC
Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With or Without Brain Metastases
Post hoc exploratory efficacy and safety outcomes from the phase III CROWN study
EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma